

Signature of Person Mailing Paper-0

**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

☒ This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is a continuation of co-pending application Serial No. 08/822,128 filed on March 21, 1997, no copies of the cited references are included as they were submitted in the prior application Serial No. 08/822,128 filed on March 21, 1997 or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

☐ However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

☐ This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

☐ The fee due under 37 CFR § 1.17(p) is submitted herewith.

☐ A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

☐ This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

**STATEMENT UNDER 37 CFR § 1.97(e):**

☐ Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

☐ No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

☐ A check in the amount of \_\_\_\_\_ is enclosed for the above fee(s).


☐ Please charge \_\_\_\_\_ to Deposit Account No. **12-2475** for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,  
LYON & LYON LLP

Dated: February 26, 2002

By: \_\_\_\_\_

  
Kurt T. Mulville  
Reg. No. 37,194



**22249**

LYON & LYON LLP  
633 W. Fifth Street, Suite  
4700  
Los Angeles, CA 90071  
949/567-2300 X 1124  
Tel.  
213/955-0440 Fax

**LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT**
**(Use several sheets if necessary)**
**APPLICANT:**

GORDON B. MILLS et al.

**FILING DATE:**

Herewith

**PREVIOUS GROUP:**

1642

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	4,693,971	9/15/87	Misaki			
	4,698,299	10/6/87	Janoff et al.			
	5,122,454	6/16/92	Ueda et al.			
	5,277,917	1/11/94	Xu et al.			
	5,326,690	7/5/94	Xu et al.			
	5,489,580	2/6/96	Markiyannis et al.			
	5,824,555		Xu et al.			

10/085979  
10/085979  
02/26/02

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	210 691	3/31/07	German			
	882 048	9/4/80	Belgium			
	63-13644	1/20/88	Japan			
	WO 89/01773	3/9/89	PCT			
	EP O 322 262	6/28/89	EPO			
	2-107195	4/19/90	Japan			
	WO 90/10448	9/20/90	PCT			
	WO 93/11136	6/10/93	PCT			
	8-53475	2/27/96	Japan			
	WO 97/45727		PCT			
	WO 01/38870 AQ		PCT			

OC-104434.1

Y. EYLER

**DATE CONSIDERED:**

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  <b>(Use several sheets if necessary)</b>	<b>ATTY. DOCKET NO.</b> 272/015	<b>SERIAL NO.</b> Not Yet Assigned
	<b>APPLICANT:</b> GORDON B. MILLS et al.	
	<b>FILING DATE:</b> Herewith	<b>PREVIOUS GROUP:</b> 1642

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
		Asaoka et al., (1992) "Role of lysophosphatidylcholine in T-lymphocyte activation: Involvement of phospholipase A <sub>2</sub> in signal transduction through protein kinase C," Proc. Natl Acad. Sci. USA 89:6447-6451
		Bligh and Dyer, (1950) "A rapid method of total lipid extraction and purification," Can. J. Biochem. Physiol. 37(8):911-917
		Domansky, V. (1992) "Functional condition and phospholipid profile of red blood cells in breast cancer patients," Vopr. Onkol. 38(10):1194-1202 (English and Russian translations previously provided)
		Dorum et al. (1996) "Early detection of familial ovarian cancer," E. J. Cancer 32A(10):1645-1651
		Einhorn et al., (1992) "Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer," Obstet. Gynecol. 80(1):14-18
		Fukami et al., (1988), "Antibody to phosphatidylinositol 4,5-bisphosphate inhibits oncogene-induced mitogenesis," Proc. Nat'l Acad. Sci. USA 85:9057-9061
		Gaudette et al. (1993), "Mass and fatty acid composition of the 3-phosphorylated phosphatidylinositol bisphosphate isomer in stimulated human platelets," J. Biol. Chem. 268(19): 13773-13776
		Gillet et al (1975), "Plasma concentrations of lysolecithin and other phospholipids in the healthy population and in men suffering from atherosclerotic diseases" Atherosclerosis 22:111-124
		Jacobs et al (1988), "Multimodal approach to screening for ovarian cancer," Lancet Feb. 6, 1988 Vol 268-271
		Jacobs et al (1996), "Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study," BMJ 313:1355-1358
		Jalink et al (1994), "Growth factor-like effects of lysophosphatidic acid, a novel lipid mediator," Biochim. Biophys. Acta 1198:185-1976
		Kalnova (1989), "Relationship between antioxidant activity and lipid profile of blood as marker of the effect of tumor on the host," Vopr. Onkol. 35(7):785-801 (English and Russian translations provided)
		Keating et al (1996), "Inhibition of protein synthesis in frog (Xenopus Laevis) egg extracts by an antibody against phosphatidylinositol 4,5-bisphosphate," Biochem J. 317(3):643-646
		Kriat et al (1993), "Analysis of plasma lipids by NMR spectroscopy: Application to modifications induced by malignant tumors," J. Lipid Res. 34:1009-1019
		Kume and Gimbrone (1994), "Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells," J. Clin. Invest. 93:907-911
		Matuoka et al (1988), "Mitogenesis in response to PDGF and bombesin abolished by microinjection of antibody to PIP <sub>2</sub> ," Science 239:640-643
		Mills et al (1988), "A putative new growth factor in ascitic fluid from ovarian cancer patients: Identification, characterization, and mechanism of action," Cancer Research 48:1066-1071
		Mills et al (1990), "Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells," J. Clin. Invest. 86:851-855
		Moolenaar (1995), "Lysophosphatidic acid signalling," Current Opinion in Cell. Biol. 7:203-210
		Moolenaar (1992), "Lysophosphatidic acid: A bioactive phospholipid with growth factor-like properties," Rev. Physiol. Biochem. Pharmacol. 119:47-65
		Muto et al (1993), "Screening for Ovarian Cancer: The preliminary experience of a familial ovarian cancer center," Gynecologic Oncol. 51:12-20
		Nakano et al (1994), "Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes," Proc. Natl Acad. Sci USA 91:1069-1073

<b>OC-104434.1</b> Y. EYLER	<b>DATE CONSIDERED:</b>
<b>EXAMINER:</b> Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  <b>(Use several sheets if necessary)</b>	<b>ATTY. DOCKET NO.</b> 272/015	<b>SERIAL NO.</b> Not Yet Assigned
	<b>APPLICANT:</b> GORDON B. MILLS et al.	
	<b>FILING DATE:</b> Herewith	<b>PREVIOUS GROUP:</b> 1642

	Okita, Misako, "Abnormality in plasma lysophosphatidic [sic] acid of ovarian cancer patients," Dept. of Nutritional Sci., Okayama Prefectural Univ., March 31, 1995, pp. 29-35 (Japanese and English translation previously provided)
	Okita et al (1997), "Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (LYSOPC) in ovarian cancer patients," Int. J. Cancer 71:31-34
	Phillips et al (1967), "Composition of phospholipids and of phospholipid fatty acids of human plasma," J. Lipid Res. 8:676-681
	Ross (1993) "The pathogenesis of atherosclerosis" A perspective for the 1990s," Nature (London) 362:801-809
	Sasaki et al (1993) "Potentiation of diacylglycerol-induced activation of protein kinase C by lysophospholipids," FEBS Letters 320(1):47-51
	Schapiro et al (1993), "The effectiveness of ovarian cancer screening: A decision analysis model," Ann. Intern. Med. 118(11):838-843
	Shen et al. (1997), "Evaluation of lysophosphatidic acid (LPA) as a diagnostic marker for ovarian cancer and other gynecological cancers," Clinical Chemistry 43(6):S230
	Skeaff et al (1987); "Effect of dietary fish oil containing eicosapentaenoic acid on the fatty acid composition of platelet phospholipids and on the thrombin-stimulated phospholipid alterations in human platelets," Colloque INSERM 152:63-76
	Skipski et al (1967), "Lipid composition of human serum lipoproteins," Biochem J. 104:340-352
	Steinberg et al (1989), "Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity," N. Eng. J. Med. 320(14):915-924
	Thomas et al (1991), "Eicosanoid-dependent and -independent formation of individual [ <sup>14</sup> C]stearoyl-labeled lysophospholipids in collagen-stimulated human platelets," Biochim. Biophys. Acta 1081:92-98
	Tokumura et al (1986), "Involvement of lysophospholipase D in the production of lysophosphatidic acid in rat plasma," Biochim Biophys. Acta 875:31-38
	Xu et al (1995), "Lysophospholipids activate ovarian and breast cancer cells," Biochem J. 309:933-940
	Xu et al (1995), "Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients," Clin. Cancer Res. 1:1223-1232
	Xu et al (1995) "Effect of Lysophospholipids on Signaling in the Human Jurkat T Cell Line," J. Cell Physiol 163:441-450
	Yoshida et al (1992), "Platelet activation by simultaneous actions of diacylglycerol and unsaturated fatty acids," Proc. Natl. Acad. Sci. USA 89:6443-6446

<b>OC-104434.1</b> Y. EYLER	<b>DATE CONSIDERED:</b>
<b>EXAMINER:</b> Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	